C 
Charles River Laboratories International CRL · USD
Health Care · Life Sciences Tools & Services · US listing · 🇺🇸 United States
S&P 500
353.34
+4.69%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$4.02bn
FY2016FY2025
Net income
−$144.3m
FY2016FY2025
Free cash flow
$518.5m
FY2016FY2025
Shareholders' equity
$3.16bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02bn | $4.05bn | $4.13bn | $3.98bn | $3.54bn | $2.92bn | $2.62bn | $2.27bn | $1.86bn | $1.68bn |
| Gross profit | $1.23bn | $1.33bn | $1.50bn | $1.46bn | $1.33bn | $1.07bn | $958.3m | $840.1m | $700.9m | $644.0m |
| Operating income | $507.8m | $219.4m | $617.3m | $651.0m | $589.9m | $518.3m | $351.2m | $331.4m | $317.4m | $237.6m |
| Net income | −$144.3m | $10.3m | $474.6m | $486.2m | $391.0m | $364.3m | $252.0m | $226.4m | $123.4m | $154.8m |
| Diluted earnings per share | -2.93 | 0.20 | 9.19 | 9.46 | 7.58 | 7.14 | 5.05 | 4.60 | 2.61 | 3.21 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.14bn | $7.53bn | $8.20bn | $7.60bn | $7.02bn | $5.49bn | $4.69bn | $3.86bn | $2.93bn | $2.71bn |
| Cash and short-term investments | $213.8m | $194.6m | $276.8m | $233.9m | $246.3m | $229.4m | $239.0m | $195.4m | $163.8m | $117.6m |
| Total liabilities | $3.92bn | $4.02bn | $4.54bn | $4.58bn | $4.43bn | $3.35bn | $3.03bn | $2.52bn | $1.87bn | $1.86bn |
| Debt | $2.20bn | $2.35bn | $3.09bn | $2.71bn | $2.70bn | $2.00bn | $1.91bn | $1.67bn | $1.15bn | $1.24bn |
| Shareholders' equity | $3.16bn | $3.46bn | $3.60bn | $2.98bn | $2.53bn | $2.11bn | $1.63bn | $1.32bn | $1.05bn | $836.8m |
| Shares outstanding | 49m | 51m | 52m | 51m | 52m | 51m | 50m | 49m | 47m | 48m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $737.6m | $734.6m | $683.9m | $619.6m | $760.8m | $546.6m | $480.9m | $441.1m | $316.3m | $298.3m |
| Capital spending | −$219.2m | −$233.0m | −$318.5m | −$324.7m | −$228.8m | −$166.6m | −$140.5m | −$140.1m | −$82.4m | −$55.3m |
| Free cash flow | $518.5m | $501.6m | $365.4m | $294.9m | $532.0m | $380.0m | $340.4m | $301.1m | $233.8m | $243.0m |
| Dividends paid | — | — | −$25.6m | — | −$45.7m | −$46.6m | −$34.5m | — | — | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00bn | $995.8m | $994.2m | $1.00bn | $1.03bn | $984.2m | $1.00bn | $1.01bn |
| Gross profit | $363.4m | $279.3m | $328.9m | $352.1m | $383.5m | $340.1m | $319.7m | $367.8m |
| Operating income | $82.5m | $119.9m | $120.2m | $151.1m | $132.3m | $98.5m | $90.2m | $148.1m |
| Net income | −$1.5m | −$14.8m | −$276.6m | $54.4m | $52.3m | $25.5m | −$215.7m | $68.7m |
| Diluted earnings per share | -0.03 | -0.31 | -5.62 | 1.10 | 1.06 | 0.50 | -4.22 | 1.33 |
| Cash from operations | $179.0m | $41.0m | $147.0m | $213.0m | $204.0m | $171.0m | $159.0m | $251.0m |
| Capital spending | −$31.0m | −$55.0m | −$88.0m | −$35.0m | −$35.0m | −$59.0m | −$75.0m | −$38.0m |
| Free cash flow | $148.0m | −$14.0m | $59.0m | $178.0m | $169.0m | $112.0m | $84.0m | $213.0m |
| Total assets | $7.53bn | $7.73bn | $7.14bn | $7.51bn | $7.56bn | $7.58bn | $7.53bn | $8.00bn |
| Cash and short-term investments | $192.0m | $191.8m | $213.8m | $207.7m | $182.8m | $229.4m | $194.6m | $210.2m |
| Debt | $2.62bn | $2.66bn | $2.20bn | $2.19bn | $2.33bn | $2.51bn | $2.24bn | $2.37bn |
| Shareholders' equity | $2.84bn | $2.94bn | $3.16bn | $3.41bn | $3.35bn | $3.19bn | $3.46bn | $3.78bn |
Financial ratios
Data as of 10 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 30.5% | 32.9% | 36.4% | 36.8% | 37.7% | 36.7% |
| Operating margin | 0.2% | 5.4% | 17.4% | 17.2% | 15.7% | 18.2% |
| Net margin | -3.6% | 0.3% | 11.5% | 12.2% | 11.0% | 12.5% |
| Return on equity | -4.6% | 0.3% | 13.2% | 16.3% | 15.4% | 17.2% |
| Return on assets | -2.0% | 0.1% | 5.8% | 6.4% | 5.6% | 6.6% |
| Free cash flow yield | 6.4% | 6.3% | 6.4% | 6.1% | 6.4% | 4.6% |
| Revenue growth | -0.9% | -1.9% | 3.9% | 12.3% | 21.1% | 11.5% |
| Earnings growth | -1501.7% | -97.8% | -2.4% | 24.4% | 7.3% | 44.6% |
| Current ratio | 1.29x | 1.41x | 1.52x | 1.32x | 1.23x | 1.43x |
| Debt to equity | 0.69x | 0.68x | 0.86x | 0.93x | 1.06x | 0.94x |
| Equity ratio | 44.4% | 46.0% | 43.9% | 39.1% | 36.1% | 38.5% |
| Interest coverage | 0.07x | 1.74x | 5.25x | 11.51x | 7.50x | 6.17x |
| Buybacks as a share of market value | 3.8% | 0.9% | -0.5% | 0.3% | -1.0% | -2.3% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 0.3% | 6.5% | 11.4% |
| Operating income | -7.9% | -0.4% | 9.4% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 31.7% | 34.2% | 35.0% | 35.8% |
| Operating margin | 9.0% | 12.3% | 13.7% | 14.0% |
| Net margin | -1.7% | 5.1% | 7.0% | 7.7% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | -68.0 | — | 25.7 | 23.0 | 49.7 | 35.0 | 30.2 | 24.6 | 42.0 | 23.8 |
| Price to sales | 2.4 | 2.3 | 3.0 | 2.8 | 5.5 | 4.4 | 2.9 | 2.5 | 2.8 | 2.2 |
Market value over time
30 Nov 2016 to 9 Oct 2026, in USD
$3.41bn$14.63bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 6% | -22% | 9% | -40% | 43% | 65% | 33% | 4% | 45% | -4% |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.